We are live on ! Find out more
MLA

MB, Levis & Associates Portfolio holdings

AUM $240M
1-Year Est. Return 12.17%
This Fund
S&P 500
This Quarter Est. Return
-0.17%
1 Year Est. Return
+12.17%
3 Year Est. Return
+32.71%
5 Year Est. Return
10 Year Est. Return
AUM
$240M
AUM Growth
+$2.13M
Cap. Flow
+$4.23M
Cap. Flow %
1.76%
Top 10 Hldgs %
63.69%
Holding
256
New
11
Increased
72
Reduced
31
Closed
22

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$137K
2
KMI icon
Kinder Morgan
KMI
+$46.9K
3
MRK icon
Merck
MRK
+$36.8K
4
ADP icon
Automatic Data Processing
ADP
+$25.7K
5
NEE icon
NextEra Energy
NEE
+$22.8K

Sector Composition

Rank Sector Weight
1 Technology 5.21%
2 Industrials 4.87%
3 Healthcare 3.48%
4 Financials 2.88%
5 Consumer Staples 2.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STRT icon
251
STRATTEC Security
STRT
$344M
-35
Closed -$2.67K
STT icon
252
State Street
STT
$50.1B
-37
Closed -$4.77K
TFPM icon
253
Triple Flag Precious Metals
TFPM
$5.71B
-116
Closed -$3.85K
ETHA
254
iShares Ethereum Trust ETF
ETHA
$5.35B
-25
Closed -$561
BKV
255
BKV Corp
BKV
$2.83B
-250
Closed -$6.79K
GRNY
256
FundStrat Granny Shots US Large Cap ETF
GRNY
$4.35B
-275
Closed -$6.81K

Similar funds

MB, Levis & Associates's Q1 2026 Portfolio in Review

As of Q1 2026, MB, Levis & Associates held 256 positions worth $240M, up 0.9% from $238M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

MB, Levis & Associates's Q1 2026 filing shows 11 new, 72 increased, 31 reduced and 22 closed positions. Its largest new stake was Essential Utilities: 951 shares worth $38.3K. The largest sale was AstraZeneca, an estimated $137K.

By sector, the portfolio is most concentrated in Technology at 5.2% of assets, down from 6.2% a quarter earlier, followed by Industrials and Healthcare.

  • MB, Levis & Associates's largest Q1 2026 buy was Essential Utilities: 951 shares worth $38.3K.
  • MB, Levis & Associates added most to T. Rowe Price Dividend Growth ETF in Q1 2026, an estimated $1.52M increase.
  • MB, Levis & Associates's biggest Q1 2026 reduction was Kinder Morgan, cutting an estimated $46.9K.
  • MB, Levis & Associates fully exited AstraZeneca in Q1 2026, selling an estimated $137K.
  • MB, Levis & Associates's ten largest holdings make up 64% of its $240M portfolio in Q1 2026.
  • MB, Levis & Associates opened 11 new positions and closed 22 in Q1 2026.
  • MB, Levis & Associates's portfolio value rose 0.9% quarter-over-quarter to $240M.

Based on MB, Levis & Associates's 13F filing for Q1 2026, filed 8 Apr 2026.